Procoagulant activity in children and adolescents on intensive insulin therapy
Background Type 1 diabetes is associated with atherothrombosis, but limited data exist on procoagulant activity in the young. We investigated procoagulant activity in children/adolescents with type 1 diabetes using intensified insulin treatment compared with controls in a 5‐year follow‐up study, and...
Gespeichert in:
| Veröffentlicht in: | Pediatric diabetes 2020-05, Vol.21 (3), p.496-504 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 504 |
|---|---|
| container_issue | 3 |
| container_start_page | 496 |
| container_title | Pediatric diabetes |
| container_volume | 21 |
| creator | Bratseth, Vibeke Margeirsdottir, Hanna D. Heier, Martin Solheim, Svein Arnesen, Harald Dahl‐Jørgensen, Knut Seljeflot, Ingebjørg |
| description | Background
Type 1 diabetes is associated with atherothrombosis, but limited data exist on procoagulant activity in the young. We investigated procoagulant activity in children/adolescents with type 1 diabetes using intensified insulin treatment compared with controls in a 5‐year follow‐up study, and further any associations with cardiovascular risk factors.
Methods
The study included 314 diabetes children/adolescents and 120 healthy controls. Prothrombin fragment 1+2 (F1+2), D‐dimer, tissue‐factor‐procoagulant‐activity (TF‐PCA), and tissue‐factor‐pathway‐inhibitor (TFPI) were analyzed with ELISAs.
Results
F1+2, D‐dimer, and TF‐PCA did not differ between the groups or correlate to HbA1c in the diabetes group at either time points. TFPI was significantly higher in the diabetes group compared with controls both at inclusion and follow‐up (both P |
| doi_str_mv | 10.1111/pedi.12978 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_crist</sourceid><recordid>TN_cdi_cristin_nora_10852_81298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2395437227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3328-ebcde28377fe780e3c2cd30a127b83e84235f5d4a84db5746ae4e14aaa5180c93</originalsourceid><addsrcrecordid>eNp9kctKBDEQRYMovjd-gDa4EWHGzqNNshSfA6IuFNyFTFKjkZ5kTLqV-XtLR124sDZVkMOt1L2E7NB6SLGOZuDDkDIt1RJZp1zrQSOEWv6d-eMa2Sjlpa6p1FyskjVOteCNYuvk5i4nl-xT39rYVdZ14S108yrEyj2H1meIlY2-sj61UBzErlQp4nMHsYQ3wKn0LdLdM2Q7m2-RlYltC2x_903ycHF-f3o1uL69HJ2eXA8c50wNYOw8MMWlnIBUNXDHnOe1pUyOFQclGG8mjRdWCT9upDi2IIAKa21DVe003yR7C12XQ-lCNDFla2itGmYUWqGQOFgQs5xeeyidmQY8oMU7IfXFMM611A36h-j-H_Ql9Tni_5HS6J9kTCJ1-LMylZJhYmY5TG2e41rzmYP5zMF85YDw7rdkP56C_0V_jEeALoD30ML8Hylzd342Woh-ALg0kZk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2395437227</pqid></control><display><type>article</type><title>Procoagulant activity in children and adolescents on intensive insulin therapy</title><source>NORA - Norwegian Open Research Archives</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bratseth, Vibeke ; Margeirsdottir, Hanna D. ; Heier, Martin ; Solheim, Svein ; Arnesen, Harald ; Dahl‐Jørgensen, Knut ; Seljeflot, Ingebjørg</creator><creatorcontrib>Bratseth, Vibeke ; Margeirsdottir, Hanna D. ; Heier, Martin ; Solheim, Svein ; Arnesen, Harald ; Dahl‐Jørgensen, Knut ; Seljeflot, Ingebjørg</creatorcontrib><description>Background
Type 1 diabetes is associated with atherothrombosis, but limited data exist on procoagulant activity in the young. We investigated procoagulant activity in children/adolescents with type 1 diabetes using intensified insulin treatment compared with controls in a 5‐year follow‐up study, and further any associations with cardiovascular risk factors.
Methods
The study included 314 diabetes children/adolescents and 120 healthy controls. Prothrombin fragment 1+2 (F1+2), D‐dimer, tissue‐factor‐procoagulant‐activity (TF‐PCA), and tissue‐factor‐pathway‐inhibitor (TFPI) were analyzed with ELISAs.
Results
F1+2, D‐dimer, and TF‐PCA did not differ between the groups or correlate to HbA1c in the diabetes group at either time points. TFPI was significantly higher in the diabetes group compared with controls both at inclusion and follow‐up (both P < .001). In the diabetes group, TFPI correlated significantly to HbA1c at both time points (r = 0.221 and 0.304, both P < .001). At follow‐up, females using oral contraceptives had significantly elevated F1+2, D‐dimer, and TF‐PCA and lower TFPI compared to no‐users (all P < .005), and females had lower TFPI (P = .017) and higher F1+2 compared with males (P = .052), also after adjusting for the use of oral contraceptives.
Conclusions
The current results show similar procoagulant activity in children/adolescents with type 1 diabetes compared with controls over a 5‐year period, indicating that these children using modern intensified insulin treatment are not at high thrombotic risk at younger age. The elevated levels of TFPI in the diabetes group, related to hyperglycaemia, are probably reflecting increased endothelial activation. These findings highlight the significance of optimal blood glucose control in children/adolescents with type 1 diabetes, to maintain a healthy endothelium.</description><identifier>ISSN: 1399-543X</identifier><identifier>EISSN: 1399-5448</identifier><identifier>DOI: 10.1111/pedi.12978</identifier><identifier>PMID: 31943582</identifier><language>eng</language><publisher>Former Munksgaard: John Wiley & Sons A/S</publisher><subject>Adolescents ; Birth control ; Blood glucose ; Cardiovascular diseases ; childhood diabetes ; Children ; Diabetes ; Diabetes mellitus (insulin dependent) ; endothelial dysfunction ; Endothelium ; hyperglycaemia ; Hyperglycemia ; Insulin ; Oral contraceptives ; procoagulant activity ; Prothrombin ; Risk factors ; Teenagers ; tissue‐factor‐pathway‐inhibitor</subject><ispartof>Pediatric diabetes, 2020-05, Vol.21 (3), p.496-504</ispartof><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3328-ebcde28377fe780e3c2cd30a127b83e84235f5d4a84db5746ae4e14aaa5180c93</citedby><cites>FETCH-LOGICAL-c3328-ebcde28377fe780e3c2cd30a127b83e84235f5d4a84db5746ae4e14aaa5180c93</cites><orcidid>0000-0003-2775-4219</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpedi.12978$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpedi.12978$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,778,782,883,1414,26554,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31943582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bratseth, Vibeke</creatorcontrib><creatorcontrib>Margeirsdottir, Hanna D.</creatorcontrib><creatorcontrib>Heier, Martin</creatorcontrib><creatorcontrib>Solheim, Svein</creatorcontrib><creatorcontrib>Arnesen, Harald</creatorcontrib><creatorcontrib>Dahl‐Jørgensen, Knut</creatorcontrib><creatorcontrib>Seljeflot, Ingebjørg</creatorcontrib><title>Procoagulant activity in children and adolescents on intensive insulin therapy</title><title>Pediatric diabetes</title><addtitle>Pediatr Diabetes</addtitle><description>Background
Type 1 diabetes is associated with atherothrombosis, but limited data exist on procoagulant activity in the young. We investigated procoagulant activity in children/adolescents with type 1 diabetes using intensified insulin treatment compared with controls in a 5‐year follow‐up study, and further any associations with cardiovascular risk factors.
Methods
The study included 314 diabetes children/adolescents and 120 healthy controls. Prothrombin fragment 1+2 (F1+2), D‐dimer, tissue‐factor‐procoagulant‐activity (TF‐PCA), and tissue‐factor‐pathway‐inhibitor (TFPI) were analyzed with ELISAs.
Results
F1+2, D‐dimer, and TF‐PCA did not differ between the groups or correlate to HbA1c in the diabetes group at either time points. TFPI was significantly higher in the diabetes group compared with controls both at inclusion and follow‐up (both P < .001). In the diabetes group, TFPI correlated significantly to HbA1c at both time points (r = 0.221 and 0.304, both P < .001). At follow‐up, females using oral contraceptives had significantly elevated F1+2, D‐dimer, and TF‐PCA and lower TFPI compared to no‐users (all P < .005), and females had lower TFPI (P = .017) and higher F1+2 compared with males (P = .052), also after adjusting for the use of oral contraceptives.
Conclusions
The current results show similar procoagulant activity in children/adolescents with type 1 diabetes compared with controls over a 5‐year period, indicating that these children using modern intensified insulin treatment are not at high thrombotic risk at younger age. The elevated levels of TFPI in the diabetes group, related to hyperglycaemia, are probably reflecting increased endothelial activation. These findings highlight the significance of optimal blood glucose control in children/adolescents with type 1 diabetes, to maintain a healthy endothelium.</description><subject>Adolescents</subject><subject>Birth control</subject><subject>Blood glucose</subject><subject>Cardiovascular diseases</subject><subject>childhood diabetes</subject><subject>Children</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>endothelial dysfunction</subject><subject>Endothelium</subject><subject>hyperglycaemia</subject><subject>Hyperglycemia</subject><subject>Insulin</subject><subject>Oral contraceptives</subject><subject>procoagulant activity</subject><subject>Prothrombin</subject><subject>Risk factors</subject><subject>Teenagers</subject><subject>tissue‐factor‐pathway‐inhibitor</subject><issn>1399-543X</issn><issn>1399-5448</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>3HK</sourceid><recordid>eNp9kctKBDEQRYMovjd-gDa4EWHGzqNNshSfA6IuFNyFTFKjkZ5kTLqV-XtLR124sDZVkMOt1L2E7NB6SLGOZuDDkDIt1RJZp1zrQSOEWv6d-eMa2Sjlpa6p1FyskjVOteCNYuvk5i4nl-xT39rYVdZ14S108yrEyj2H1meIlY2-sj61UBzErlQp4nMHsYQ3wKn0LdLdM2Q7m2-RlYltC2x_903ycHF-f3o1uL69HJ2eXA8c50wNYOw8MMWlnIBUNXDHnOe1pUyOFQclGG8mjRdWCT9upDi2IIAKa21DVe003yR7C12XQ-lCNDFla2itGmYUWqGQOFgQs5xeeyidmQY8oMU7IfXFMM611A36h-j-H_Ql9Tni_5HS6J9kTCJ1-LMylZJhYmY5TG2e41rzmYP5zMF85YDw7rdkP56C_0V_jEeALoD30ML8Hylzd342Woh-ALg0kZk</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Bratseth, Vibeke</creator><creator>Margeirsdottir, Hanna D.</creator><creator>Heier, Martin</creator><creator>Solheim, Svein</creator><creator>Arnesen, Harald</creator><creator>Dahl‐Jørgensen, Knut</creator><creator>Seljeflot, Ingebjørg</creator><general>John Wiley & Sons A/S</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>3HK</scope><orcidid>https://orcid.org/0000-0003-2775-4219</orcidid></search><sort><creationdate>202005</creationdate><title>Procoagulant activity in children and adolescents on intensive insulin therapy</title><author>Bratseth, Vibeke ; Margeirsdottir, Hanna D. ; Heier, Martin ; Solheim, Svein ; Arnesen, Harald ; Dahl‐Jørgensen, Knut ; Seljeflot, Ingebjørg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3328-ebcde28377fe780e3c2cd30a127b83e84235f5d4a84db5746ae4e14aaa5180c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescents</topic><topic>Birth control</topic><topic>Blood glucose</topic><topic>Cardiovascular diseases</topic><topic>childhood diabetes</topic><topic>Children</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>endothelial dysfunction</topic><topic>Endothelium</topic><topic>hyperglycaemia</topic><topic>Hyperglycemia</topic><topic>Insulin</topic><topic>Oral contraceptives</topic><topic>procoagulant activity</topic><topic>Prothrombin</topic><topic>Risk factors</topic><topic>Teenagers</topic><topic>tissue‐factor‐pathway‐inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bratseth, Vibeke</creatorcontrib><creatorcontrib>Margeirsdottir, Hanna D.</creatorcontrib><creatorcontrib>Heier, Martin</creatorcontrib><creatorcontrib>Solheim, Svein</creatorcontrib><creatorcontrib>Arnesen, Harald</creatorcontrib><creatorcontrib>Dahl‐Jørgensen, Knut</creatorcontrib><creatorcontrib>Seljeflot, Ingebjørg</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><jtitle>Pediatric diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bratseth, Vibeke</au><au>Margeirsdottir, Hanna D.</au><au>Heier, Martin</au><au>Solheim, Svein</au><au>Arnesen, Harald</au><au>Dahl‐Jørgensen, Knut</au><au>Seljeflot, Ingebjørg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Procoagulant activity in children and adolescents on intensive insulin therapy</atitle><jtitle>Pediatric diabetes</jtitle><addtitle>Pediatr Diabetes</addtitle><date>2020-05</date><risdate>2020</risdate><volume>21</volume><issue>3</issue><spage>496</spage><epage>504</epage><pages>496-504</pages><issn>1399-543X</issn><eissn>1399-5448</eissn><abstract>Background
Type 1 diabetes is associated with atherothrombosis, but limited data exist on procoagulant activity in the young. We investigated procoagulant activity in children/adolescents with type 1 diabetes using intensified insulin treatment compared with controls in a 5‐year follow‐up study, and further any associations with cardiovascular risk factors.
Methods
The study included 314 diabetes children/adolescents and 120 healthy controls. Prothrombin fragment 1+2 (F1+2), D‐dimer, tissue‐factor‐procoagulant‐activity (TF‐PCA), and tissue‐factor‐pathway‐inhibitor (TFPI) were analyzed with ELISAs.
Results
F1+2, D‐dimer, and TF‐PCA did not differ between the groups or correlate to HbA1c in the diabetes group at either time points. TFPI was significantly higher in the diabetes group compared with controls both at inclusion and follow‐up (both P < .001). In the diabetes group, TFPI correlated significantly to HbA1c at both time points (r = 0.221 and 0.304, both P < .001). At follow‐up, females using oral contraceptives had significantly elevated F1+2, D‐dimer, and TF‐PCA and lower TFPI compared to no‐users (all P < .005), and females had lower TFPI (P = .017) and higher F1+2 compared with males (P = .052), also after adjusting for the use of oral contraceptives.
Conclusions
The current results show similar procoagulant activity in children/adolescents with type 1 diabetes compared with controls over a 5‐year period, indicating that these children using modern intensified insulin treatment are not at high thrombotic risk at younger age. The elevated levels of TFPI in the diabetes group, related to hyperglycaemia, are probably reflecting increased endothelial activation. These findings highlight the significance of optimal blood glucose control in children/adolescents with type 1 diabetes, to maintain a healthy endothelium.</abstract><cop>Former Munksgaard</cop><pub>John Wiley & Sons A/S</pub><pmid>31943582</pmid><doi>10.1111/pedi.12978</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2775-4219</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1399-543X |
| ispartof | Pediatric diabetes, 2020-05, Vol.21 (3), p.496-504 |
| issn | 1399-543X 1399-5448 |
| language | eng |
| recordid | cdi_cristin_nora_10852_81298 |
| source | NORA - Norwegian Open Research Archives; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescents Birth control Blood glucose Cardiovascular diseases childhood diabetes Children Diabetes Diabetes mellitus (insulin dependent) endothelial dysfunction Endothelium hyperglycaemia Hyperglycemia Insulin Oral contraceptives procoagulant activity Prothrombin Risk factors Teenagers tissue‐factor‐pathway‐inhibitor |
| title | Procoagulant activity in children and adolescents on intensive insulin therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T05%3A08%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_crist&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Procoagulant%20activity%20in%20children%20and%20adolescents%20on%20intensive%20insulin%20therapy&rft.jtitle=Pediatric%20diabetes&rft.au=Bratseth,%20Vibeke&rft.date=2020-05&rft.volume=21&rft.issue=3&rft.spage=496&rft.epage=504&rft.pages=496-504&rft.issn=1399-543X&rft.eissn=1399-5448&rft_id=info:doi/10.1111/pedi.12978&rft_dat=%3Cproquest_crist%3E2395437227%3C/proquest_crist%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2395437227&rft_id=info:pmid/31943582&rfr_iscdi=true |